Upcoming Dividend • May 07
Upcoming dividend of HK$0.24 per share Eligible shareholders must have bought the stock before 14 May 2026. Payment date: 03 June 2026. Payout ratio is on the higher end at 82%, and the cash payout ratio is above 100%. Trailing yield: 8.4%. Within top quartile of Hong Kong dividend payers (6.8%). Higher than average of industry peers (4.3%). Reported Earnings • Apr 02
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: CN¥0.26 (down from CN¥0.28 in FY 2024). Revenue: CN¥1.36b (down 3.2% from FY 2024). Net income: CN¥183.4m (down 6.0% from FY 2024). Profit margin: 14% (in line with FY 2024). Revenue missed analyst estimates by 7.0%. Earnings per share (EPS) also missed analyst estimates by 7.1%. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 18% per year, which means it is performing significantly worse than earnings. Announcement • Mar 31
Chaoju Eye Care Holdings Limited, Annual General Meeting, May 12, 2026 Chaoju Eye Care Holdings Limited, Annual General Meeting, May 12, 2026. Announcement • Mar 09
Chaoju Eye Care Holdings Limited to Report Fiscal Year 2025 Results on Mar 31, 2026 Chaoju Eye Care Holdings Limited announced that they will report fiscal year 2025 results on Mar 31, 2026 Announcement • Jan 02
Chaoju Eye Care Holdings Limited Announces Executive Changes, Effective January 1, 2026 Chaoju Eye Care Holdings Limited announced that Mr. Cheng Ching Kit has resigned from his position as a joint company secretary of the Company, with effect from 1 January 2026. He has also resigned from his role as the authorised representative of the Company with effect from 1 January 2026. The Board also announced that Mr. LO Wai Kin Kent has been appointed as the company secretary of the Company, Authorised Representative and Process Agent with effect from 1 January 2026. Mr. Lo is currently the managing director of V-Solutions Group Limited and has over 10 years of experiences in the company secretarial and corporate governance industries. Mr. Lo is an associate member of the Hong Kong
Chartered Governance Institute, the Chartered Governance Institute in the United Kingdom and CPA Australia. Mr. Lo graduated from York University in Canada with a bachelor's
degree in commerce. He also holds a master's degree in corporate governance from Saint Francis University in Hong Kong. Reported Earnings • Sep 02
First half 2025 earnings released: EPS: CN¥0.16 (vs CN¥0.20 in 1H 2024) First half 2025 results: EPS: CN¥0.16 (down from CN¥0.20 in 1H 2024). Revenue: CN¥698.3m (down 4.9% from 1H 2024). Net income: CN¥113.6m (down 17% from 1H 2024). Profit margin: 16% (down from 19% in 1H 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 7.8% growth forecast for the Healthcare industry in Hong Kong. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Announcement • Aug 15
Chaoju Eye Care Holdings Limited to Report Q2, 2025 Results on Aug 29, 2025 Chaoju Eye Care Holdings Limited announced that they will report Q2, 2025 results on Aug 29, 2025 Announcement • Jul 03
Chaoju Eye Care Holdings Limited Appoints Guo Hongyan as Member of the Nomination Committee, Effective June 30, 2025 The board of directors of Chaoju Eye Care Holdings Limited announced that, for the purpose of complying with the revised Corporate Governance Code as set out in Appendix C1 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited to be effective from July 1, 2025, Ms. GUO Hongyan, an independent non-executive Director, has been appointed as a member of the nomination committee of the Board with effect from June 30, 2025. Following the above changes, the Nomination Committee comprises three independent non- executive Directors (namely Mr. HE Mingguang, Ms. GUO Hongyan, and Mr. BAO Shan) and one executive Director (namely Mr. ZHANG Bozhou), and has comprised at least one director of a different gender. Announcement • Jun 06
Chaoju Eye Care Holdings Limited Approves Final Dividend for the Year Ended December 31, 2024 Chaoju Eye Care Holdings Limited at its AGM held on June 6, 2025 approved to declare a final dividend of HKD 0.1193 per share for the year ended December 31, 2024. Upcoming Dividend • Jun 03
Upcoming dividend of HK$0.12 per share Eligible shareholders must have bought the stock before 10 June 2025. Payment date: 27 June 2025. Payout ratio is on the higher end at 83%, however this is supported by cash flows. Trailing yield: 8.5%. Within top quartile of Hong Kong dividend payers (7.7%). Higher than average of industry peers (4.1%). Announcement • Mar 27
Chaoju Eye Care Holdings Limited, Annual General Meeting, Jun 06, 2025 Chaoju Eye Care Holdings Limited, Annual General Meeting, Jun 06, 2025. Reported Earnings • Mar 27
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CN¥0.28 (down from CN¥0.33 in FY 2023). Revenue: CN¥1.41b (up 2.6% from FY 2023). Net income: CN¥195.1m (down 15% from FY 2023). Profit margin: 14% (down from 17% in FY 2023). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 8.2%. Earnings per share (EPS) also missed analyst estimates by 21%. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 6.9% growth forecast for the Healthcare industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Announcement • Mar 17
Chaoju Eye Care Holdings Limited Announces Joint Company Secretary Changes Chaoju Eye Care Holdings Limited announced that Ms. XIE Chun ("Ms. Xie") has tendered her resignation as a joint company secretary of the Company (the "Joint Company Secretary") with effect from March 17, 2025, in order to devote more time to other business commitment. The Board hereby announces that upon the resignation of Ms. Xie, Mr. ZHANG Guangdi ("Mr. Zhang") has been appointed as a Joint Company Secretary for a term of three years with effect from March 17, 2025, and after the aforesaid changes, Mr. CHENG Ching Kit ("Mr. Cheng") will continue to serve as the other Join Company Secretary. Mr. Zhang, aged 32, has been an executive Director since May 19, 2020 and his main responsibilities include assisting the facilitation of operation and related management plans of the Group. Currently, he also serves as a director of Chaoju Medical Technology Co. Ltd. and the general manager of Chaoju Eye Care (HK) Company Limited. Mr. Zhang has been the investment manager at Beijing Chaoju Investment Management Co. Ltd. since August 2021 preceded by his role as the director of operations at the refractive correction department at Chaoju (Inner Mongolia) Eye Hospital Co. Ltd. He was also employed as the general manager of Sihong Chaoju Eye Hospital Co. Ltd. from April 2018 to September 2019 and the assistant to general manager at Jiangsu Chaoju Medical Management Co. Ltd. from July 2015 to April 2018. Mr. Zhang graduated from Inner Mongolia University in Inner Mongolia, China with a bachelor's degree in Financial Management in June 2014. Mr. Cheng, was appointed as a Joint Company Secretary on December 21, 2020. He is currently an assistant vice president of SWCS Corporate Services Group (Hong Kong) Limited, a professional service provider specializing in corporate services. He has over 12 years of experience in the company secretarial profession. Mr. Cheng graduated from the University of Queensland, Australia with a bachelor's degree in commerce (finance) in December 2010 and graduated from the University of Hong Kong with a master's degree in law (Chinese law) in November 2022. He has been an associate member of both the Hong Kong Chartered Governance Institute and the Chartered Governance Institute in the United Kingdom since June 2018. Announcement • Mar 14
Chaoju Eye Care Holdings Limited to Report Fiscal Year 2024 Results on Mar 26, 2025 Chaoju Eye Care Holdings Limited announced that they will report fiscal year 2024 results on Mar 26, 2025 Valuation Update With 7 Day Price Move • Oct 01
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to HK$3.46, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 12x in the Healthcare industry in Hong Kong. Total loss to shareholders of 55% over the past three years. Upcoming Dividend • Sep 04
Upcoming dividend of HK$0.13 per share Eligible shareholders must have bought the stock before 11 September 2024. Payment date: 25 September 2024. Payout ratio is a comfortable 61% and this is well supported by cash flows. Trailing yield: 7.6%. Lower than top quartile of Hong Kong dividend payers (8.4%). Higher than average of industry peers (4.5%). Reported Earnings • Aug 31
First half 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.21 in 1H 2023) First half 2024 results: EPS: CN¥0.20 (down from CN¥0.21 in 1H 2023). Revenue: CN¥734.3m (up 6.0% from 1H 2023). Net income: CN¥136.5m (down 9.4% from 1H 2023). Profit margin: 19% (down from 22% in 1H 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Healthcare industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings. Announcement • Aug 29
Chaoju Eye Care Holdings Limited Announces Interim Dividend for the Six Months Ended 30 June 2024, Payable on 25 September 2024 Chaoju Eye Care Holdings Limited announced interim dividend of HKD 0.1307 per share for the six months ended 30 June 2024. Ex-dividend date: 11 September 2024. Record date: 17 September 2024. Payment date: 25 September 2024. Announcement • Aug 12
Chaoju Eye Care Holdings Limited to Report First Half, 2024 Results on Aug 29, 2024 Chaoju Eye Care Holdings Limited announced that they will report first half, 2024 results on Aug 29, 2024 Valuation Update With 7 Day Price Move • Jun 18
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to HK$3.03, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 9x in the Healthcare industry in Hong Kong. Total loss to shareholders of 24% over the past year. Announcement • Jun 08
Chaoju Eye Care Holdings Limited Approves Final Dividend for the Year Ended December 31, 2023 Chaoju Eye Care Holdings Limited at its annual general meeting held on June 6, 2024, approved a final dividend of HKD 0.2208 per share for the year ended December 31, 2023. Upcoming Dividend • Jun 05
Upcoming dividend of HK$0.30 per share Eligible shareholders must have bought the stock before 12 June 2024. Payment date: 28 June 2024. Payout ratio is a comfortable 61% and this is well supported by cash flows. Trailing yield: 6.1%. Lower than top quartile of Hong Kong dividend payers (7.6%). Higher than average of industry peers (3.5%). Reported Earnings • Apr 28
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2023 results: EPS: CN¥0.33 (up from CN¥0.27 in FY 2022). Revenue: CN¥1.37b (up 38% from FY 2022). Net income: CN¥228.9m (up 22% from FY 2022). Profit margin: 17% (down from 19% in FY 2022). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 5.1%. Earnings per share (EPS) missed analyst estimates by 8.3%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare industry in Hong Kong. Announcement • Apr 28
Chaoju Eye Care Holdings Limited, Annual General Meeting, Jun 06, 2024 Chaoju Eye Care Holdings Limited, Annual General Meeting, Jun 06, 2024, at 10:00 China Standard Time. Location: Room 2403, 24/F, Block A, Shouke Building, Taipingqiao Street, Fengtai District, Beijing, China Beijing China Agenda: To receive, consider and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors of the Company and auditor of the Company for the year ended December 31, 2023; to declare a final dividend of HK $0.2208 per share for the year ended December 31, 2023; to re-appoint Ernst & Young as the auditors of the Company and authorize the Board to fix remuneration of auditors; to re-elect Ms. ZHANG Li as a non-executive Director; to re-elect Mr. HE Mingguang as an independent non-executive Director; to re-elect Ms. GUO Hongyan as an independent non-executive Director; to re-elect Mr. LI Jianbin as an independent non-executive Director; to re-elect Mr. BAO Shan as an independent non-executive Director; to authorize the board of Directors to fix remuneration of the Directors; and to consider other matters. Announcement • Mar 27
Chaoju Eye Care Holdings Limited, Annual General Meeting, Jun 06, 2024 Chaoju Eye Care Holdings Limited, Annual General Meeting, Jun 06, 2024. Reported Earnings • Mar 27
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2023 results: EPS: CN¥0.33 (up from CN¥0.27 in FY 2022). Revenue: CN¥1.37b (up 38% from FY 2022). Net income: CN¥228.9m (up 22% from FY 2022). Profit margin: 17% (down from 19% in FY 2022). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 5.1%. Earnings per share (EPS) missed analyst estimates by 8.3%. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Healthcare industry in Hong Kong. Announcement • Mar 15
Chaoju Eye Care Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024 Chaoju Eye Care Holdings Limited announced that they will report fiscal year 2023 results on Mar 26, 2024 Reported Earnings • Aug 31
First half 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.15 in 1H 2022) First half 2023 results: EPS: CN¥0.21 (up from CN¥0.15 in 1H 2022). Revenue: CN¥692.7m (up 30% from 1H 2022). Net income: CN¥150.6m (up 45% from 1H 2022). Profit margin: 22% (up from 19% in 1H 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Healthcare industry in Hong Kong. Announcement • Aug 22
Chaoju Eye Care Holdings Limited Provides Consolidated Earning Guidance for the Six Months Ended June 30, 2023 Chaoju Eye Care Holdings Limited provided consolidated earning guidance for the six months ended June 30, 2023. For the period, the Group expects to record a revenue in the range of RMB 670 million to RMB 720 million for the six months ended June 30, 2023, representing an increase of approximately 26% to 35%, as compared to a revenue of RMB 532.7 million for the corresponding period in 2022; and a net profit in the range of RMB 140 million to RMB 155 million for the six months ended June 30, 2023, representing an increase of approximately 38% to 52%, as compared to a net profit of RMB101.8 million for the corresponding period in 2022. Based on information currently available, the Board considers that such expected increases are primarily attributable to, among other things, the following reasons: (i) the recovery of demand for opthalmic services, owing to the increased corporate efficiency which enhanced the Group's reception capacity for patient visits, the recovery of the industry and the general economic environment in the PRC after the COVID-19 pandemic, which led to an overall increase of the Group's revenue; and (ii) the growth in net profit due to higher gross profit margin resulted from the expansion of consumer opthalmic services and basic opthalmic services businesses after the COVID-19 pandemic as well as better economies of scale so derived. Announcement • Aug 12
Chaoju Eye Care Holdings Limited to Report First Half, 2023 Results on Aug 29, 2023 Chaoju Eye Care Holdings Limited announced that they will report first half, 2023 results on Aug 29, 2023 Buying Opportunity • Jul 07
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 15%. The fair value is estimated to be HK$5.25, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 19% per annum. Earnings is also forecast to grow by 20% per annum over the same time period. Buying Opportunity • Jun 14
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 23%. The fair value is estimated to be HK$5.32, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 19% per annum. Earnings is also forecast to grow by 20% per annum over the same time period. Announcement • Jun 13
Chaoju Eye Care Holdings Limited Announces Board Changes Chaoju Eye Care Holdings Limited announces that, with effect from June 12, 2023, Ms. Zhang Wenwen has resigned as a non-executive Director due to her intention to pursue other personal commitment and interests. The Board further announces that Ms. Zhang Li has been appointed as a non-executive Director with effect from June 12, 2023. Ms. Zhang Li, aged 35, has over 10 years of experience in wealth management matters. She has joined Group as a director of Chaoju Medical Technology Co. Ltd. since June 2023. Ms. Zhang Li has been acting as a vice president of investor relations and a manager of post-investment management at Riverhead Capital Investment Management Co. Ltd. since September 2018. Prior to that, she has worked at Sunshine Life Insurance Corporation Limited between June 2013 and August 2018 and was primarily responsible for management reporting and group accounting. Ms. Zhang Li obtained a bachelor's degree in accounting from Shandong University of Finance and Economics in China in July 2010 and a master's degree in finance from Beijing Technology and Business University in June 2013. Announcement • Jun 07
Chaoju Eye Care Holdings Limited Approves Dividend Final Dividend for the Year Ended December 31, 2022 Chaoju Eye Care Holdings Limited at the AGM held on June 6, 2023 approved to declare a final dividend of HKD 0.1738 per share for the year ended December 31, 2022. Upcoming Dividend • Jun 05
Upcoming dividend of HK$0.17 per share at 3.8% yield Eligible shareholders must have bought the stock before 12 June 2023. Payment date: 28 June 2023. Payout ratio is a comfortable 58% and this is well supported by cash flows. Trailing yield: 3.8%. Lower than top quartile of Hong Kong dividend payers (7.8%). Higher than average of industry peers (2.8%). Valuation Update With 7 Day Price Move • May 25
Investor sentiment deteriorates as stock falls 22% After last week's 22% share price decline to HK$4.26, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 12x in the Healthcare industry in Hong Kong. Total returns to shareholders of 37% over the past year. Simply Wall St's valuation model estimates the intrinsic value at HK$5.35 per share. Buying Opportunity • May 25
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 26%. The fair value is estimated to be HK$5.35, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 19% per annum. Earnings is also forecast to grow by 20% per annum over the same time period. Valuation Update With 7 Day Price Move • Apr 14
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to HK$5.80, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 12x in the Healthcare industry in Hong Kong. Total returns to shareholders of 55% over the past year. Simply Wall St's valuation model estimates the intrinsic value at HK$7.27 per share. Reported Earnings • Mar 29
Full year 2022 earnings: EPS in line with expectations, revenues disappoint Full year 2022 results: EPS: CN¥0.27 (up from CN¥0.26 in FY 2021). Revenue: CN¥990.0m (flat on FY 2021). Net income: CN¥187.8m (up 16% from FY 2021). Profit margin: 19% (up from 16% in FY 2021). Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Healthcare industry in Hong Kong. Valuation Update With 7 Day Price Move • Feb 15
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to HK$6.25, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 13x in the Healthcare industry in Hong Kong. Total returns to shareholders of 31% over the past year. Simply Wall St's valuation model estimates the intrinsic value at HK$5.04 per share. Valuation Update With 7 Day Price Move • Jan 05
Investor sentiment improved over the past week After last week's 20% share price gain to HK$5.04, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 14x in the Healthcare industry in Hong Kong. Total loss to shareholders of 14% over the past year. Buying Opportunity • Jan 04
Now 20% undervalued Over the last 90 days, the stock is up 15%. The fair value is estimated to be HK$5.47, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.7% over the last year. Earnings per share has declined by 12%. Revenue is forecast to grow by 62% in 2 years. Earnings is forecast to grow by 64% in the next 2 years. Buying Opportunity • Dec 14
Now 22% undervalued Over the last 90 days, the stock is up 6.0%. The fair value is estimated to be HK$5.42, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.7% over the last year. Earnings per share has declined by 12%. Revenue is forecast to grow by 62% in 2 years. Earnings is forecast to grow by 64% in the next 2 years. Valuation Update With 7 Day Price Move • Dec 02
Investor sentiment improved over the past week After last week's 16% share price gain to HK$3.45, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 14x in the Healthcare industry in Hong Kong. Total loss to shareholders of 45% over the past year. Board Change • Nov 16
Less than half of directors are independent There are 8 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 independent directors. 8 non-independent directors. Non-Executive Director Zhen Li was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Valuation Update With 7 Day Price Move • Oct 27
Investor sentiment deteriorated over the past week After last week's 15% share price decline to HK$2.96, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 13x in the Healthcare industry in Hong Kong. Total loss to shareholders of 63% over the past year. Reported Earnings • Aug 31
First half 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.15 in 1H 2021) First half 2022 results: EPS: CN¥0.15. Revenue: CN¥532.7m (up 6.5% from 1H 2021). Net income: CN¥103.6m (up 28% from 1H 2021). Profit margin: 19% (up from 16% in 1H 2021). The increase in margin was driven by higher revenue. Announcement • Aug 18
Chaoju Eye Care Holdings Limited to Report First Half, 2022 Results on Aug 29, 2022 Chaoju Eye Care Holdings Limited announced that they will report first half, 2022 results on Aug 29, 2022 Recent Insider Transactions • Jul 15
Insider recently bought HK$2.9m worth of stock On the 11th of July, Fengsheng Zhang bought around 648k shares on-market at roughly HK$4.42 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought HK$5.8m more in shares than they have sold in the last 12 months. Announcement • Jun 23
Chaoju Eye Care Holdings Limited Announces Executive Changes Chaoju Eye Care Holdings Limited announced the resignation of Wang Weichao as a joint company secretary of the Company ("Joint Company Secretary") and the secretary to the board of the Company. The board of the Company (the "Board") announced that Ms. Xie Chun ("Ms. Xie") has been appointed as a Joint Company Secretary in replacement of Mr. WangWeichao and the chief strategy officer of the Company with effect from June 22, 2022. Mr. Cheng Ching Kit ("Mr. Cheng") will continue to act as the other Joint Company Secretary. Ms. Xie, aged 41, has joined the Group since January 2022 as the secretary to the Board, mainly responsible for the company secretarial work and regulatory compliance affairs of the Group. Ms. Xie has over 19 years of experience in the fields of law, finance and investment. Prior to joining the Group, Ms. Xie was the vice president of Zhongqinhe Asset Management Co. Ltd. from November 2019 to January 2022, responsible for equity investment and internal control. Ms. Xie also served as the vice president of finance in Jilin Changjiu Industrial Group Co. Ltd. from October 2013 to October 2019, responsible for strategic investment, capital operation and financial business, preceded by her roles as the vice president and board secretary of Xi'an Xidianjietong Radio Network Co. Ltd. from July 2010 to October 2013, responsible for securities, investment, legal and intellectual property affairs. Earlier on in her career, Ms. Xie served as the head of the capital market department of Zhong Yin Law Firm from June 2005 to June 2010 with a focus on securities and capital market business. Ms. Xie obtained her bachelor's degree in law from Zhongnan University of Economics and Law in June 2003. Ms. Xie has also obtained the board secretary qualification issued by the Shenzhen Stock Exchange in October 2011. Valuation Update With 7 Day Price Move • Jun 23
Investor sentiment improved over the past week After last week's 16% share price gain to HK$4.08, the stock trades at a trailing P/E ratio of 15.2x. Average trailing P/E is 17x in the Healthcare industry in Hong Kong. Announcement • Jun 07
Chaoju Eye Care Holdings Limited Approves Final Dividend for the Year Ended December 31, 2021 Chaoju Eye Care Holdings Limited at Annual General Meeting Held on June 6, 2022, approved to declare a final dividend of HKD 0.1043 per share for the year ended December 31, 2021. Board Change • Apr 27
Less than half of directors are independent There are 8 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 independent directors. 8 non-independent directors. Non-Executive Director Zhen Li was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Valuation Update With 7 Day Price Move • Apr 05
Investor sentiment improved over the past week After last week's 16% share price gain to HK$4.06, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 11x in the Healthcare industry in Hong Kong. Reported Earnings • Mar 30
Full year 2021 earnings: Revenues miss analyst expectations Full year 2021 results: Revenue: CN¥997.8m (up 26% from FY 2020). Net income: CN¥161.7m (up 30% from FY 2020). Profit margin: 16% (in line with FY 2020). Revenue missed analyst estimates by 2.4%. Over the next year, revenue is forecast to grow 35%, compared to a 34% growth forecast for the industry in Hong Kong. Valuation Update With 7 Day Price Move • Mar 08
Investor sentiment deteriorated over the past week After last week's 17% share price decline to HK$4.06, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 12x in the Healthcare industry in Hong Kong. Valuation Update With 7 Day Price Move • Jan 25
Investor sentiment deteriorated over the past week After last week's 15% share price decline to HK$4.90, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 15x in the Healthcare industry in Hong Kong. Valuation Update With 7 Day Price Move • Dec 03
Investor sentiment deteriorated over the past week After last week's 16% share price decline to HK$6.47, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 17x in the Healthcare industry in Hong Kong. Valuation Update With 7 Day Price Move • Nov 19
Investor sentiment improved over the past week After last week's 17% share price gain to HK$8.47, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 20x in the Healthcare industry in Hong Kong. Recent Insider Transactions • Nov 11
Chairman & CEO recently bought HK$321k worth of stock On the 9th of November, Bozhou Zhang bought around 44k shares on-market at roughly HK$7.37 per share. This was the largest purchase by an insider in the last 3 months. Bozhou has been a buyer over the last 12 months, purchasing a net total of HK$571k worth in shares. Valuation Update With 7 Day Price Move • Sep 15
Investor sentiment deteriorated over the past week After last week's 18% share price decline to HK$8.56, the stock trades at a trailing P/E ratio of 30.7x. Average forward P/E is 19x in the Healthcare industry in Hong Kong. 